Clinical trials of cancer drugs in Brazil. Clinical trial in Brazil

Delhi, October 4, 2024 (GLOBE NEWSWIRE) — Insight into cancer drug clinical trials in Brazil 2024 Report offer:

• Clinical Trials Market Opportunities in Brazil 2024 and 2030 (US$ Million)
• Regulatory framework for clinical trials in Brazil
• Total number of cancer drugs in clinical trials in Brazil
• Total number of cancer drugs approved in Brazil
• 400 pages of insight into clinical studies of all cancer drugs in clinical trials by company, indication and phase
• 80 pages of clinical insights into all cancer drugs approved on the market by company and indication
• Insight into 25 pharmaceutical companies and CRO in Brazil

Download report:

The clinical trial landscape for cancer drugs in Brazil has evolved rapidly in recent years, making the country an increasingly important player in global oncology research. As the largest country in Latin America with a population of over 215 million and a diverse genetic makeup, Brazil offers unique opportunities for conducting clinical trials in oncology. The Brazilian clinical trial environment is characterized by a mix of private and public healthcare systems, providing researchers with access to a wide range of patient populations. This diversity is particularly valuable in cancer research, where genetic and environmental factors can significantly influence treatment outcomes. Major cities such as Rio de Janeiro, São Paulo and Porto Alegre have become centers of clinical research and are home to state-of-the-art medical and research facilities.

One of the main reasons for Brazil's growing importance in cancer drug trials is the country's high cancer burden. It is estimated that Brazil recorded around 630,000 new cases of cancer in 2022 and is expected to reach 750,000 by 2030. This high incidence rate, coupled with the need for innovative treatments, has given a major impetus to conducting oncology trials in the country. Breast, prostate, colorectal and lung cancers are among the most common types and are in line with global trends and research priorities.

The regulatory landscape for clinical trials in Brazil has improved significantly in recent years. The Agência Nacional de Vigilância Sanitária (ANVISA) has streamlined the i8ts approval processes, shortening the timelines for initiating trials. The creation of the Rede Nacional de Pesquisa Clínica (RNPC) has also facilitated the implementation of multicenter studies throughout the country. These regulatory advances have made Brazil more attractive to international pharmaceutical companies and research organizations seeking to conduct global studies.

Through Brazil's participation in international collaborative research networks, the country has further strengthened its position in cancer drug trials. The country is increasingly participating in global Phase III trials, giving Brazilian patients access to cutting-edge experimental therapies. This involvement not only contributes to global drug development, but also helps build local expertise and infrastructure to conduct complex oncology trials.

The Brazilian government has also played a role in promoting cancer research through initiatives such as the National Policy for Cancer Care (PNAO). This policy aims to improve cancer care across the country and includes provisions to support clinical research. In addition, public-private partnerships have emerged as a key strategy for advancing cancer drug development in Brazil, combining government resources with private sector expertise and funding.

However, challenges remain in Brazil's clinical trial landscape. Differences in access and quality of healthcare between urban and rural areas may impact patient recruitment and trial conduct. Language barriers and the need to translate exam materials can also increase the complexity of international studies. Furthermore, despite improvements, it can still be difficult for foreign sponsors unfamiliar with local processes to navigate the Brazilian regulatory system.

Another important aspect of the Brazilian cancer drug trial landscape is the focus on biosimilars and generics. As patents on several key cancer drugs expire, Brazil has become an important market for the development and testing of biosimilars. This is in line with the country's efforts to improve access to cancer treatments and reduce healthcare costs.

Looking to the future, Brazil's cancer drug clinical trial landscape promises continued growth and innovation. The country's large and diverse patient population, improving regulatory environment and growing expertise in oncology research make it an attractive destination for global cancer drug development. As Brazil continues to invest in its research infrastructure and capabilities, the country is poised to play an increasingly important role in advancing cancer treatments on a global scale.